Intertek Pharmaceutical Services’ Post

Your one-stop-shop for many things mRNA🤝 ...Don't just take our word for it - check out what some of our expert speakers have to say about the 4th mRNA-Based Therapeutics Summit this July! Get your copy of the three-day program here, jam-packed with four tracks' worth of mRNA content: https://ter.li/s9qfa7 #mRNA #mRNATherapeutics #mRNAVaccines #RNA #WorldRNA #mRNASummit

Intrahepatic Cholangiocarcinoma Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapy: Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Intrahepatic Cholangiocarcinoma pipeline constitutes 20+ key companies continuously working towards developing 20+ Intrahepatic Cholangiocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Choosing the right partners for your IVT mRNA synthesis workflow is critical in the path to developing mRNA therapeutics. Start your DNA plasmid template on the right foot with our ISO 13485 certified competent cells that are tailored to your research needs. https://hubs.li/Q02R6lTx0 #mRNAsynthesis #mRNAtherapeutics #mRNAvaccines #mRNAresearch

You won't want to miss the upcoming webinar on the HEAL #Pain Therapeutics Development Program (#PTDP). Monday July 29, 2024 3:00 PM ET. This webinar will inform and provide participants with an opportunity to ask questions about PTDP and the #NIH funding announcement, RFA-NS-24-019 whose purpose is to support #preclinical optimization and development of safe, effective, and #nonaddictive small molecule and biologic therapeutics to treat pain. The goal of PTDP is to accelerate promising early therapeutic molecules and facilitate their readiness for the Early Phase Pain Investigation Clinical Network (EPPIC-Net) or other Phase II clinical studies. Link to register for the webinar: https://lnkd.in/g4ftETip

Humanized animal models are critical tools to facilitate efficacy evaluation of novel anti-human antibody therapeutics. Many of Biocytogen’s humanized mouse models have been engineered to specifically express human forms of immune-checkpoints and/or cytokine signaling molecules on an immunocompetent background. These models offer a robust and cost-effective way to evaluate in vivo therapeutic efficacy of biologics. If you’re attending AACR, check out our 11 posters featuring our off-the-shelf mouse/rat models, or set up a meeting at booth 939:  https://lnkd.in/dTTkD7z3 #AACR2024 #AACRConference #AACRMeeting #CancerAwareness #TumorResearch #immunodeficient #preclinicalresearch #immunotherapy #cancerresearch #cancertherapy #PreclinicalStudies #HumanizedModels #renbiologics #antibodylibrary

Session spotlight 🌟 At the mRNA-Based Therapeutics Summit Europe, Maren von Fritschen, PhD, Shirley Hopper, Constanze Blume, Julia Djonova and Ulrike Jaegle will lead the panel discussion on “A European Industry & Regulatory Perspective on the Development & Approval of mRNA Medicines”. To dive deeper into this exciting session and more, view the event program: https://lnkd.in/e6zrkvWC #rna #mrnaeurope #mrna #messengerrna

The GW Technology Commercialization Office is delighted to share that The George Washington University Hospital along with UC Irvine and Northwell Health provided Hoth Therapeutics, Inc written approval for First-in-Human (FIH) Phase 2a clinical trial of Topical HT-001 gel. HT-001 is a proprietary gel formulation for topical application developed by Hoth Therapeutics, a patient-focused, clinical-stage biopharmaceutical company. The Phase 2a study will investigate efficacy, safety, and tolerability of application of HT-001 gel, while also focusing on the therapeutic effect of HT-001 in adult subjects and patients for treatment of cutaneous toxicity (skin, scalp, nails) associated with Epidermal Growth Factor Receptor Inhibitors (EGFRI) cancer therapy. Read more: https://lnkd.in/dhj7mYW4 The HT-001 gel is a significant leap towards treating skin disorders induced by EGFRI therapy and has potential to improve patient care. We look forward to the outcomes of the trials and positive impact the gel could have on patients’ lives. #GW #GWTCO #GWHospital #SkinDisorder #CancerTherapy #Healthcare #ClinicalTrails #Pharmaceutical 

Photys Therapeutics entered a multi-year collaboration and license agreement with Novo Nordisk to develop proximity-based therapeutics for a cardiometabolic disease target leveraging Photys’ PHosphorylation Inducing Chimeric Small molecules technology. https://hubs.li/Q0309GTD0

Intrahepatic Cholangiocarcinoma Pipeline Insights 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics: Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Intrahepatic Cholangiocarcinoma pipeline constitutes 20+ key companies continuously working towards developing 20+ Intrahepatic Cholangiocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Percheron Therapeutics ends clinical trial in Australia and Europe after data indicates no benefits after 6 months of treatment with avicursen (ATL1102) #CureDuchenne #duchennemusculardystrophy #duchenne #musculardystrophy #percheronTherapeutics https://lnkd.in/gP9TnMcr